Verrica Interim CFO John J. Kirby acquires $24,650 of common sharesPUBT·1 day ago, 04:01 PMVRCA+6.62%
Verrica Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 5.862 MEarnings Watch·Aug 6 at 05:32 PMVRCA+6.62%
Verrica Q2 FY26 net loss widens to $13.2 million; revenue drops 53.85% to $5.9 millionPUBT·Aug 6 at 03:35 PMVRCA+6.62%
Verrica Pharmaceuticals closes credit facility for up to $27.5 million with entity controlled by Chairman Paul ManningPUBT·Aug 6 at 03:02 PMVRCA+6.62%
Verrica Pharmaceuticals (VRCA) Projected to Release Quarterly Earnings on ThursdayMarket Beat·Aug 2 at 04:56 AMVRCA+6.62%
Verrica Pharmaceuticals schedules conference call to discuss Q2 results, corporate updatePUBT·Jul 30 at 07:08 AMVRCA+6.62%
Fed Rate Jitters Send Ripples Through Fringe Assets and Yield-Sensitive ETFsGlobal Report·Jul 30 at 04:13 AMOPI-5.37%VRCA+6.62%
Verrica signs exclusive deal with Medomie to market Ycanth in IsraelPUBT·Jul 21 at 07:07 AMVRCA+6.62%
H.C. Wainwright Sticks to Their Buy Rating for Verrica Pharmaceuticals (VRCA)Tip Ranks·Jun 22 at 09:15 AMVRCA+6.62%
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts | VRCA Stock NewsStockTitan·Jun 21 at 11:05 PMVRCA+6.62%4551
